無料セミナー : 2020年3月4日『Future of Immuno-Oncology 免疫腫瘍学の未来』 DelveInsight Business Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

がん免疫療法の世界市場:需要分析・機会評価

Global Immuno-Oncology Market Demand Analysis & Opportunity Evaluation, 2019-2027

発行 Research Nester 商品コード 915927
出版日 ページ情報 英文 189 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.91円で換算しております。
Back to Top
がん免疫療法の世界市場:需要分析・機会評価 Global Immuno-Oncology Market Demand Analysis & Opportunity Evaluation, 2019-2027
出版日: 2019年10月19日 ページ情報: 英文 189 Pages
概要

世界のがん免疫療法市場は、2018年に538億5,948万米ドルと評価され、2027年にかけては12.68%のCAGRで1,572億3,048万米ドル規模の市場に成長すると予測されています。地域別では、2018年に世界シェアの48.13%を獲得し最大市場となった北米が今後もその優勢を維持する見通しです。

当レポートでは、世界のがん免疫療法市場を調査し、市場の概要、市場動向、製品・投与経路・エンドユーザー・地域別の市場規模の推移と予測、市場の成長要因および課題の分析、パイプラインおよび治験動向、規制環境、リスク分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

  • イントロダクション
  • 市場定義と市場概要
  • 製品定義
  • 調査目的
  • エグゼクティブサマリー
  • がん免疫療法:市場力学
  • 市場の成長要因
  • 市場の課題
  • 市場動向
  • 市場機会
  • 産業分析
  • 疫学分析
  • がん免疫療法併用療法の調査
  • パイプライン・治験分析
  • 政策・規制環境
  • リスク分析
  • 世界のがん免疫療法市場
  • 市場概要 - 市場規模の推移と予測
  • 市場区分:製品別
  • 市場区分:投与経路別
  • 市場区分:エンドユーザー別
  • 市場区分:地域別
  • 競合情勢
  • 企業の市場ポジショニング
  • 主要企業のプロファイル
  • F. Hoffmann-La Roche Ltd
  • Merck & Company, Inc.
  • AstraZeneca Plc.
  • Novartis
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen
  • GlaxoSmithKline plc.
  • Strategic Recommendations
目次

The global immuno-oncology treatment market reached USD 53,859.48 million in 2018 and is expected to reach USD 157,230.48 million by 2027, by registering a CAGR of 12.68%, across the globe. This is primarily attributed to the rising concerns over hospital acquired infections across the globe.

North America captured a share of 48.13% in the year 2018 and is expected to dominate the market, over the forecast period. The growth in the region can be attributed to increase in investments towards healthcare from government and private entities to maintain the highest quality of care offered in healthcare facilities. The US is the major country driving the growth in the region, reaching a market value of USD 24,040.00 million in 2018 and is expected to grow at a CAGR of 13.14% over the forecast period i.e. 2020-2027. On the back of rising adoption of innovative treatment modalities focused on personalized medicine, it is expected to result in the market growth over the forecast period.

Availability of advanced diagnostic products that are capable of effectively diagnosing rare cancers are resulting in increasing number of people availing early treatment. The Asia Pacific region captured a market size of USD 10,560.34 million in the year 2018 and is expected to reach USD 32,498.22 million by 2027, with a CAGR of 13.32%. The market is primarily led by the demand from China, with a market of USD 4,199.90 million in the year 2018, and it is expected to grow at a CAGR of 14.54%. With the rising availability of advanced pharmaceuticals in this region, with rising number of products being approved in countries such as China, Japan, & India, to address the growing number of cancer patients in this region, the demand for immuno-oncology treatment products in this region is expected to witness a rapid growth over the forecast period.

Europe is expected to reach a market size of USD 36,620.08 million by 2027. It has been observed that with the availability of innovative treatment modalities, there has been a shift in treatment preferences from conventionally prescribed chemotherapy products to advanced and highly targeted treatment products. Although these products are relatively higher priced, there is an increasing number of patients opting for these products as along with a superior mode of action providing a faster recovery, they also enable a better quality of life during the treatment course with reduced side effects. Over the recent years, it has been observed that the European Union has been increasingly approving large number of immuno-oncology products such as cellular immunotherapy and immune checkpoint inhibitors. Although the presence of biosimilars in this region have affected the revenue recognition of certain products (Rituximab), this region is expected to generate a steady demand for advanced pharmaceutical products.

On the basis of segmentation by administration, the market is divided into standalone and combination therapies from which combination therapies is presently capturing a vast majority of the market. A large number of approved products are being investigated with various combinations of other immunotherapy products or else chemotherapy drugs. This is recommended in cases when the cancer has either spread to other regions of the body or else the healthcare provided opts for a highly aggressive treatment method. However, increasing number of drugs are being studied and approved as standalone therapies especially targeting benign tumors.

On the basis of end user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others. The hospitals segment captured the largest market with USD 38,075.29 million in 2018 and is expected to reach USD 109,482.05 million by 2027 with a CAGR of 12.50% over the forecast period. This can be attributed to the high number of patients encountered by hospitals and large facilities in comparison to smaller facilities such as clinics. Some of the largest players in this market are Roche, Merck, Amgen, Janssen, Eli Lilly and Novartis

Table of Contents

  • Introduction
  • Market Definition and Market Lineage Outlook
  • Product Definition
  • Research Objective
  • Research Methodology
  • Executive Summary
  • Market Dynamics of Global Immuno-Oncology Market
  • Market Drivers
  • Market Challenges
  • Market Trends
  • Opportunities
  • Industry Analysis
  • Epidemiology Analysis
  • Cancer Immunotherapy-based Combination Studies
  • Pipeline & Clinical Trial Analysis
  • Policy & Regulatory Landscape
  • Risk Analysis
  • Global Immuno-oncology Market
  • Market Overview - Market Size and Forecast, 2018-2027
  • Market Segmentation by:
  • Product
  • Administration
  • End User
  • Region
  • Competitive Landscape
  • Competitive Positioning
  • Company Profiles of top players
  • F. Hoffmann-La Roche Ltd
  • Merck & Company, Inc.
  • AstraZeneca Plc.
  • Novartis
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen
  • GlaxoSmithKline plc.
  • Strategic Recommendations
Back to Top